Samsung is testing whether its Galaxy Watch 8 can help track and potentially mitigate muscle loss in people who start GLP-1 therapies such as Ozempic. According to multiple reports, Samsung is working with diabetes experts at Massachusetts General Hospital (Mass General) to study how wearables may support patients during GLP-1 receptor agonist (GLP-1RA) treatment.
The effort focuses on monitoring changes in activity and physiological measures over time. Sources say the study uses data from the Galaxy Watch 8, including activity tracking and heart-rate information, and also looks at body-composition or muscle-related indicators during treatment. The companies and researchers aim to observe whether these measurements can identify muscle loss patterns or help support healthier outcomes for adults beginning GLP-1RA therapy.
While the reports describe an ongoing testing and research approach, they do not provide results or confirm clinical effectiveness beyond the study’s monitoring and observation goals.
